ImmunityBio (ImmunityBio) Capex-to-Revenue : 31.53 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

ImmunityBio's Capital Expenditure for the three months ended in Mar. 2024 was $-1.26 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.04 Mil.

Hence, ImmunityBio's Capex-to-Revenue for the three months ended in Mar. 2024 was 31.53.

ImmunityBio Capex-to-Revenue Historical Data

The historical data trend for ImmunityBio's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Capex-to-Revenue Chart

ImmunityBio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Revenue

1.95

2.76

35.94

414.13

49.17

ImmunityBio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Revenue	Get a 7-Day Free Trial													23.41	207.95	69.21	57.23	31.53

Competitive Comparison of ImmunityBio's Capex-to-Revenue

For the Biotechnology subindustry, ImmunityBio's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmunityBio's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunityBio's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where ImmunityBio's Capex-to-Revenue falls into.

ImmunityBio Capex-to-Revenue Calculation

ImmunityBio's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-30.584)	/	0.622
	=	49.17

ImmunityBio's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-1.261)	/	0.04
	=	31.53

ImmunityBio (NAS:IBRX) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

ImmunityBio Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of ImmunityBio's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunityBio (ImmunityBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (NAS:IBRX) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

26CA:Germany

Address

3530 John Hopkins Court, San Diego, CA, USA, 92121

Website

https://www.immunitybio.com

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.

Executives

Patrick Soon-shiong	director, 10 percent owner, officer: See remarks	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
California Capital Equity, Llc	10 percent owner	10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Cambridge Equities, Lp	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Mp 13 Ventures, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Michael D Blaszyk	director	C/O NANTKWEST, INC., 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
John Owen Brennan	director	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Wesley Clark	director	C/O ARGYLE SECURITY ACQUISITION CORP., 200 CONCORD PLAZA, SUITE 700, SAN ANTONIO TX 78216
Regan J Lauer	officer: Chief Accounting Officer	4250 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Richard Adcock	officer: Chief Executive Officer	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Linda Maxwell	director	1040 SPRING STREET, SILVER SPRING NC 27709
Christobel Selecky	director	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David C. Sachs	officer: Chief Financial Officer	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Frederick W Driscoll	director